FDA 执法报告 D-0076-2027:Hikma 阿比特龙醋酸酯片批号 3047 因重量均匀度不合格列为 II 类召回
FDA drug enforcement D-0076-2027: Hikma Pharmaceuticals USA INC. — Failed Tablet/Capsule Specifications: Failed tablet specifications for weight uniformity.
openFDA 执法报告 D-0076-2027 显示,Hikma Pharmaceuticals USA 发起的阿比特龙醋酸酯(Abirtega)USP 250 mg 片剂召回被列为 II 类,原因是重量均匀度不符合片剂标准。
记录列出了阿比特龙醋酸酯片重量均匀度不合格召回的类别、批号与分销范围,便于核对批次追溯信息。
FDA 药品召回执法报告 — D-0076-2027
报告发布日期:2026-10-28。这是执法报告日期,不是召回启动日期。
范围:一条已分类的药品召回记录;event_id 可能归组多个产品。没有召回编号的未分类记录不在本数据流范围内。本记录不是新闻稿,也不是新的执法认定。
openFDA 数据集每周更新。报告状态不是实时召回状态,不得用于跟踪召回生命周期。以下其他日期保留其各自名称所对应的含义。
完整官方产品记录(包括 openFDA 统一标识符):
{
"address_1": "1809 Wilson Rd",
"address_2": "",
"center_classification_date": "20261023",
"city": "Columbus",
"classification": "Class II",
"code_info": "批号:3047,有效期 2027 年 7 月。",
"country": "United States",
"distribution_pattern": "美国全国范围",
"event_id": "100046",
"initial_firm_notification": "Letter",
"more_code_info": "",
"openfda": {
"application_number": [
"ANDA208339"
],
"brand_name": [
"ABIRTEGA"
],
"generic_name": [
"ABIRATERONE ACETATE"
],
"is_original_packager": [
true
],
"manufacturer_name": [
"CivicaScript, LLC"
],
"package_ndc": [
"82249-011-12"
],
"product_ndc": [
"82249-011"
],
"product_type": [
"HUMAN PRESCRIPTION DRUG"
],
"route": [
"ORAL"
],
"rxcui": [
"1100075",
"2702601"
],
"spl_id": [
"692d596d-5465-4611-82f7-5d50c37270a2"
],
"spl_set_id": [
"2f932015-28b2-4f44-ac04-772e982e13e9"
],
"substance_name": [
"ABIRATERONE ACETATE"
],
"unii": [
"EM5OCB9YJ6"
],
"upc": [
"0382249011123"
]
},
"postal_code": "43228-9579",
"product_description": "Abirtega(醋酸阿比特龙)USP,250 mg,120 片装瓶,处方药,处方药,生产商:Hikma Pharmaceuticals USA Inc.,Berkley Heights, NJ 07922 USA;由 Arab Pharmaceuticals Manufacturing PSC 生产,PO Box 41, Sahab-Jordon,NDC 82249-011-12。",
"product_quantity": "2136 瓶",
"product_type": "Drugs",
"reason_for_recall": "片剂/胶囊规格不合格:片剂重量均一性规格不合格。",
"recall_initiation_date": "20261006",
"recall_number": "D-0076-2027",
"recalling_firm": "Hikma Pharmaceuticals USA INC.",
"report_date": "20261028",
"state": "OH",
"status": "Ongoing",
"voluntary_mandated": "Voluntary: Firm initiated"
}
来源:openFDA 已分级药品召回执法报告 · api.fda.gov